PMID: 9656697Jul 10, 1998Paper

Radiobiological considerations for stereotactic irradiation

Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
N ShigematsuH Ito

Abstract

Stereotactic radiosurgery (SRS: stereotactic irradiation [STI] delivered in a single high dose) was initially developed by Leksell for non-malignant brain lesions, but there has been increasing interest in using it to treat small primary brain tumors or metastases. In more recent years, stereotactic radiotherapy (SRT: fractionated STI) has been developed, but radiobiological factors have not been sufficiently evaluated in relation to these techniques. Larson classified potential STI targets into four categories according to whether the target tissue is early- or late-responding and whether it is embedded within or only surrounded by normal tissue. We have actually calculated biologically effective doses for these categories to determine the indications for SRS and SRT, and to be able to choose suitable SRT schedules. Based on our calculations, theoretically SRS would be recommended for AVMs and benign tumors having distinct margins separating them from surrounding normal tissue and SRT would be recommended for low or high grade astrocytomas without clearly defined boundaries and metastasis. Recommended SRT schedules would be 49 Gy/7 fractions, 52 Gy/8 fractions or 54.9 Gy/9 fractions completed within 2 weeks. However, clinicall...Continue Reading

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Related Papers

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
C C Ling, C S Chui
BioMed Research International
Antonio SantacroceDaniel Hänggi
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
M DhanachaiP Yongvithisatid
© 2022 Meta ULC. All rights reserved